sb 203580 has been researched along with Nephrosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertram, JF; Campanale, NV; Deane, JA; Li, J; Liang, RJ; Ricardo, SD | 1 |
1 other study(ies) available for sb 203580 and Nephrosis
| Article | Year |
|---|---|
Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy.
Topics: Actins; Activin Receptors, Type I; Animals; Doxorubicin; Enzyme Activation; Extracellular Matrix; Fibroblasts; Fibrosis; Imidazoles; Kidney; Kidney Function Tests; Macrophages; Male; Mice; Mice, Inbred BALB C; Muscle Cells; Nephrosis; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta1; Up-Regulation | 2006 |